

Media Release**Q1 Revenue up by 27%**
(1st Quarter FY 2023 Consolidated Results)

Mumbai, 28th July, 2022: Ajanta Pharma Ltd. reported its performance for the 1st quarter ended 30th June 2022 today.

Q1 FY 2023 performance highlights (compared to Q1 FY 2022)

- Revenue from operations at Rs. 951 cr. against Rs. 748 cr.; up 27%.
- EBITDA at Rs. 222 cr. against Rs. 220 cr.; EBITDA at 23% of Revenue from Operations.
- Profit after tax at Rs. 175 cr. against Rs. 174 cr.; PAT at 18% of Revenue from Operations.

India

For **Q1** FY 2023, India sales was Rs. 279 cr. (against Rs. 229 cr.), up 22%.

As per **IQVIA MAT June 2022**, we have posted healthy growth of 10% in Cardiology (segment growth of 6%), 21% in Ophthalmology (segment growth of 20%), 20% in Dermatology (segment growth of 5%) and 23% in Pain Management (segment growth of 15%).

Exports

Q1 FY 2023, total export sales were Rs. 665 cr. (against Rs. 513 cr.) posting growth of 30%. Segment wise break-up is given below:

Emerging market branded generic	Sale was Rs. 408 cr. against (Rs. 291 cr.) posting 41% growth. Out of which: <ul style="list-style-type: none">• Africa branded generic sale was Rs. 168 cr. (against Rs. 125 cr.) posting 34% growth.• Asia branded generic sale was Rs. 240 cr. (against Rs. 165 cr.) posting 45% growth.
US Generic	Sale was Rs. 179 cr. (against Rs. 168 cr.) posting 6% growth. In US, during Q1 FY 2023 , company received 1 ANDA tentative approval and filed 1 ANDA with US FDA. Out of 42 final ANDA approvals, we have commercialized 39 products. We hold 4 tentative approval and 20 ANDAs are awaiting US FDA approval. Company plans to file 10 to 12 ANDAs during this financial year.
Africa Institution	Sale was Rs. 77 cr. (against Rs. 54 cr.) posting 44% growth.

R&D

During Q1 FY 2023, R&D expenses were Rs. 54 cr., (against Q1 FY 2022 Rs. 45 cr.) which is 6% of revenue from operations.

About Ajanta Pharma Limited

Ajanta Pharma is a specialty pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of the company's products are 1st to market and they are leading in their sub-therapeutic segments.

Company's state of the art R&D centre is located in Mumbai. Company has 7 world class manufacturing facilities located in India.

For last 10 financial years, company has posted healthy performance with its Revenue from Operations growing at 15% CAGR and net profit at 23% CAGR.

Earnings Conference Call

The Company will host an Earnings Conference Call at 1700 hrs. IST (1930 hrs. SST/HKT, 1230 hrs. BST, 0730 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	July 28, 2022 at 1700 – 1800 hrs IST 1930 – 2030 hrs SST/HKT 1230 – 1330 hrs BST 0730 – 0830 hrs US ET
Dial-in Numbers	
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
Diamond pass link	Click here to register
International Toll	USA: +1 3233868721 UK: +44 2034785524 Hong Kong: +852 30186877 Singapore: +65 31575746
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on twitter - <https://twitter.com/ajantapharmaltd>

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement